Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Linda LaRue"'
Using a mobile application to self-monitor diet and fluid intake among adults receiving hemodialysis
Autor:
Janet L, Welch, Kim Schafer, Astroth, Susan M, Perkins, Cynthia S, Johnson, Kay, Connelly, Katie A, Siek, Josette, Jones, Linda LaRue, Scott
Publikováno v:
Research in nursinghealth. 36(3)
Hemodialysis patients have difficulty self-managing a complex dietary and fluid regimen. The purpose of this feasibility study was to pilot test an electronic self-monitoring intervention based on social cognitive theory. During a six-week interventi
Autor:
Welch, Janet L., Astroth, Kim Schafer, Perkins, Susan M., Johnson, Cynthia S., Connelly, Kay, Siek, Katie A., Jones, Josette, Scott, Linda LaRue
Publikováno v:
Research in Nursing & Health; Jun2013, Vol. 36 Issue 3, p284-298, 15p
Autor:
Gary Friday, Larry Levitt, Linda LaRue, Milton Alter, Eugene Sobel, Sue M Lai, R. L. McCoy, T. Isack
Publikováno v:
Stroke. 18:565-569
A population-based study of the relation between hematocrit and stroke subtype was carried out among 2,077 individuals using the Lehigh Valley Stroke Register. This register identifies all stroke patients admitted to the 8 acute care hospitals servin
Autor:
Eugene Sobel, Linda LaRue, L. P. Levitt, R. L. McCoy, A. Gil-Peralta, Milton Alter, T. Isack, S M Lai, Gary Friday
Publikováno v:
Neurology. 39(9)
We investigated black/white differences in stroke rate (standardized morbidity), severity, and subtype, and the relative frequencies of 5 primary risk factors (hypertension, diabetes, myocardial infarction, other heart diseases, and transient ischemi
Publikováno v:
Stroke. 19(8)
Temple University Hospital participated in a multicenter acute stroke trial but enrolled only one patient out of 192 screened over 2 years; other centers had similar difficulty in patient recruitment. We analyzed our screening data to determine which
Publikováno v:
Neuroepidemiology. 6(1-2)
The design and course of a placebo-controlled alpha-2 interferon trial in MS patients are described. No beneficial effect of the interferon on the course of MS could be shown.
Publikováno v:
Controlled Clinical Trials. 9:256
Publikováno v:
Medicine and Science in Sports and Exercise. 21:S58
Autor:
Liveley, Genevieve1 (AUTHOR) g.liveley@bristol.ac.uk, Shaw, Rebecca1 (AUTHOR)
Publikováno v:
Law & Humanities. Nov2020, Vol. 14 Issue 2, p244-266. 23p.
Autor:
BENSON II, RICHARD D.
Publikováno v:
Palimpsest (2165-1604); 2021, Vol. 10 Issue 1, p43-63, 21p